The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ivanova F.G.

Yakutsk Republican Oncology Dispensary, Yakutsk, Republic of Sakha;
Yakutia Research Center for Complex Medical Problems, Siberian Branch, Russian Academy of Medical Sciences, Yakutsk, Republic of Sakha

Nikolaeva T.I.

Yakutsk Republican Oncology Dispensary, Yakutsk, Republic of Sakha;
Yakutia Research Center for Complex Medical Problems, Siberian Branch, Russian Academy of Medical Sciences, Yakutsk, Republic of Sakha

Karsybaeva N.A.

Yakutsk Republican Oncology Dispensary, Yakutsk, Republic of Sakha

Ivanov P.M.

Yakutia Research Center for Complex Medical Problems, Siberian Branch, Russian Academy of Medical Sciences, Yakutsk, Republic of Sakha;
M.K. Ammosov Medical Institute North-Eastern Federal University, Yakutsk, Republic of Sakha

Experience with targeted therapy for liver cancer in the Republic of Sakha (Yakutia)

Authors:

Ivanova F.G., Nikolaeva T.I., Karsybaeva N.A., Ivanov P.M.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2016;5(6): 77‑80

DOI: 10.17116/onkolog20165677-80

Read: 2961 times

Download PDF (RU)
Contact the author
Table of contents

EXPERIENCE WITH TARGETED THERAPY FOR LIVER CANCER IN THE REPUBLIC OF SAKHA (YAKUTIA)
EXPERIENCE WITH TARGETED THERAPY FOR LIVER CANCER IN THE REPUBLIC OF SAKHA (YAKUTIA)

To cite this article:

Ivanova FG, Nikolaeva TI, Karsybaeva NA, Ivanov PM. Experience with targeted therapy for liver cancer in the Republic of Sakha (Yakutia). P.A. Herzen Journal of Oncology. 2016;5(6):77‑80. (In Russ.)
https://doi.org/10.17116/onkolog20165677-80

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Dyna­mics of the main indi­cators of medi­cal care to the popu­lation of the Russian Fede­ration for the period 1993—2023 in the “Oncology” profile. P.A. Herzen Journal of Onco­logy. 2025;(3):71-77
Main trends in the epidemiology of mali­gnant neoplasms in the Sibe­rian Fede­ral district. P.A. Herzen Journal of Onco­logy. 2025;(4):61-68
Vaccination against pneumococcal infe­ction as a mean of redu­cing morbidity and mortality of the adult popu­lation from risk groups in the Russian Fede­ration. (Resolution of the Council of Expe­rts). Russian Journal of Preventive Medi­cine. 2025;(7):7-14
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Atte­ndance of dental surgeons for diseases in the Russian Fede­ration in 2017—2023. Stomatology. 2025;(4):62-65
Analysis of morbidity in the Gomel region of Repu­blic Bela­rus. Russian Journal of Preventive Medi­cine. 2025;(9):23-28
Current global trends in the epidemiology of inflammatory bowel diseases. Russian Journal of Evidence-Based Gastroenterology. 2025;(3):104-117
Epidemiology of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):39-54
Descriptive epidemiological study of the morbidity with here­ditary non-syndromic diso­rders of kera­tinization among the popu­lation of Moscow. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):750-759
Clinical and demo­graphic features of multiple scle­rosis in the Krasnoyarsk Krai. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):120-125
Abstract:

The paper presents data on the incidence of liver cancer related to virus hepatitis in the population of Yakutia. The analysis is based on a clinical observation and sorafenib treatment in patients with advanced hepatocellular carcinoma in the presence of chronic hepatitis B.

Keywords:

incidence
hepatocellular carcinoma
sorafenib
Child-Pugh class A

Authors:

Ivanova F.G.

Yakutsk Republican Oncology Dispensary, Yakutsk, Republic of Sakha;
Yakutia Research Center for Complex Medical Problems, Siberian Branch, Russian Academy of Medical Sciences, Yakutsk, Republic of Sakha

Nikolaeva T.I.

Yakutsk Republican Oncology Dispensary, Yakutsk, Republic of Sakha;
Yakutia Research Center for Complex Medical Problems, Siberian Branch, Russian Academy of Medical Sciences, Yakutsk, Republic of Sakha

Karsybaeva N.A.

Yakutsk Republican Oncology Dispensary, Yakutsk, Republic of Sakha

Ivanov P.M.

Yakutia Research Center for Complex Medical Problems, Siberian Branch, Russian Academy of Medical Sciences, Yakutsk, Republic of Sakha;
M.K. Ammosov Medical Institute North-Eastern Federal University, Yakutsk, Republic of Sakha

Close metadata

References:

  1. GLOBOCAN 2012 (IARC), Section of Cancer Surveillance (10/11/2014). Accessed at September 27, 2016. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
  2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-1255. doi:10.1016/s0140-6736(11)61347-0
  3. IARC. 2011. Accessed at September 27, 2016. Available at: http://www-dep.iarc.fr/
  4. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.e1. doi:10.1053/j.gastro.2011.12.061
  5. Bruix J, Calvet X, Costa J, Ventura M, Bruguera M, Castillo R et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 1989;334(8670):1004-1006. doi:10.1016/s0140-6736(89)91015-5
  6. Shiratori Y. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology. 1995;22(4):1027-1033. doi:10.1016/0270-9139(95)90605-3
  7. Kaprin A, Starinskii V, Petrova G, eds. Malignancies in Russia in 2014 (morbidity and mortality) [Zlokachestvennye novoobrazovaniya v rossii v 2014 (zabolevaemost' i smertnost')]. Moscow: MNIOI im. P.A. Gertsena — filial FGBU «FMITs im. P.A. Gertsena» Minzdrava Rossii; 2016. (In Russ.)
  8. Kolesov E, Grigor'ev V, Kornilov M et al., eds. State report «On the state sanitary and epidemiological welfare of the population in the Republic of Sakha (Yakutia) in 2014» [Gosudarstvennyi doklad «O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Respublike Sakha (Yakutiya) v 2014]. Yakutsk; 2015. Accessed at September 27, 2016. (In Russ.)
  9. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011;53(3):1020-1022. doi:10.1002/hep.24199
  10. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012;56(4):908-943. doi:10.1016/j.jhep.2011.12.001
  11. Lencioni R, Chen X-P, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist. 2010; 15(Suppl.4):42-52. doi:10.1634/theoncologist.2010-s4-42
  12. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34. doi:10.1016/s1470-2045(08)70285-7
  13. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34. doi:10.1016/s1470-2045(08)70285-7
  14. Forner A, Reig ME, Rodriguez de Lope C, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61-74. doi:10.1055/s-0030-1247133
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.